People & Profit

The business show that goes beyond the numbers and the corporate jargon! We break down major business stories and look at how they affect our lives. Thursday at 4:45pm Paris time.

  1. Jun 11

    Race for critical minerals: The social and environmental trade-off

    What are the social and environmental costs of the race for critical minerals? Minerals like cobalt, lithium, and nickel are crucial for the development of new technology, including clean energy. But mining and refining them can be hugely polluting and water intensive – with a risk of deforestation, water contamination, and health problems for local communities. Studies suggest that about half of mining projects around the world are on or near indigenous lands.  Julie Klinger, Associate Professor at the University of Wisconsin-Madison, and Edson Krenak, Brazil program manager at Cultural Survival, believe that local communities need to play a bigger role in new and existing mining projects. "What we see is a production of electric cars, digital technologies being served to the global markets, while the communities where their territories are serving these minerals are completely left behind without clean water, safe environment, without legal security," warns Krenak. "They are really facing a lot of problems for the profit, for the good or the privilege of the global north." Klinger says local populations should also have a say in what the raw materials are being used for. "For example, lithium of course is important for renewable energy technologies. Lithium is also used in a range of advanced weapons applications such as drones, smart bombs, assault rifles and tanks as well. And so if communities are going to be asked to host a mining or heavy industrial operation, that community should also know what the ultimate end use of the material is." Klinger argues that growing demand doesn't require new mining projects. "Most of the material, including designated critical minerals and elements that have been dug out of the ground for the past few centuries, still exist somewhere on the surface of the earth (...) And where these materials still exist, they actually are another kind of longstanding environmental health problem that needs to be cleaned up." "This race of more and more extraction is not building a healthy environment for our planet," agrees Krenak. "What are the new futures we are building with this new transition? We are not dreaming of a healthy future, a healthy planet for us, for our [future] generations."

  2. Jun 4

    Pharmaceutical industry becomes geopolitical battleground as US threatens tariffs

    The global pharmaceutical industry has found itself at the heart of geopolitical and trade tensions. The Trump administration has pushed policies to promote the sovereignty of US drugmakers, threatening tariffs on manufacturers or countries, and vowing to reduce prescription drug prices for Americans.  But it's an approach that could lead to "potential catastrophe", according to Karl Claxton, Professor of Economics at the University of York. "Instead of the US getting to grips with the fact that the healthcare system encourages and incentivises very high-cost medicine, instead of that, they've done a deal (...) I don't think it's going to fix the problem in the US. So I don't think US citizens will be huge beneficiaries. The rest of the world, particularly the high and middle-income countries are going to suffer unless we resist this pressure. And I think the pharmaceutical sector is going to suffer too." Claxton is sharply critical of a deal struck between the US and UK governments on drug prices. "This deal effectively doubles how much we are going to pay for all new drugs (...) Within three years, the additional cost of this deal will exceed the entire value of all [British] pharmaceutical and medical device exports to the US. So this is a really, really bad deal." He says fixing international pricing of pharmaceuticals should be a top health priority for all governments. "The impact of paying unsustainable prices for the new medicines is that all the other parts of the healthcare system that deliver really important benefits across the board end up having to accommodate that." Also in the show, France says it will be the first EU country to reimburse some obese patients for weight-loss drugs Wegovy and Mounjaro. Claxton believes the fast-growing sector offers potential health benefits and savings, but the long-term benefits have yet to be proven, and must be equally distributed. "These are potentially very valuable drugs (...) let's also make sure that those that really need it, that can benefit them and can reduce costs for our healthcare systems to benefit others, that they get access. In other words, let's not allow these drugs to be rationed according to who can afford to pay."

About

The business show that goes beyond the numbers and the corporate jargon! We break down major business stories and look at how they affect our lives. Thursday at 4:45pm Paris time.

More From FRANCE 24 English